Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
Arcadia Biosciences, Inc. (RKDA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Arcadia Biosciences Announces Second-Quarter and First-Half 2023 Financial Results and Business Highlights • GoodWheatTMexpands into breakfast category with the launch of better-for-you pancake and waffle mixes • Exiting Body Care to reduce OpEx, focus on Food & Beverage • Exploring strategic opportunities to drive shareholder value DAVIS, Calif. – Arcadia Biosciences, Inc.® , a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the second quarter and first half of 2023. “Arcadia continues to make progress executing Project Greenfield, our three-year strategic plan to unlock the company’s potential and provide a path to profitability,” said Stan Jacot, president and CEO. &#x...",
"Arcadia Biosciences, Inc. Consolidated Balance Sheets Assets Current assets: Cash and cash equivalents $ 13,484 $ 20,644 Short-term investments 5,023 — Accounts receivable and other receivables, net of allowance for doubtful accounts of $1 and $3 as of June 30, 2023 and December 31, 2022, respectively 630 1,287 Inventories, net — current 3,164 2,571 Assets held for sale 87 87 Prepaid expenses and other current assets 951 809 Total current assets 23,339 25,398 Property and equipment, net 560 704 Right of use asset 1,384 1,848 Inventories, net — noncurrent 1,297 767 Intangible assets, net 40 40 Other noncurrent assets 178 165 Total assets $ 26,798 $ 28,922 Liabilities and stockholders’ equity Current liabilities: Accounts payable and accrued expenses $ 2,783 $ 2,881 Amounts due to related p..."
07/20/2023 8-K Quarterly results
06/12/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2023 8-K Quarterly results
Docs: "Arcadia Biosciences Announces First Quarter 2023 Financial Results from Operations and Business Highlights – Significant improvement in gross profit dollars compared to last year – – GoodWheatTM pasta named “Best New Product” by Retail Dietitians Business Alliance – DAVIS, Calif. – Arcadia Biosciences, Inc.® , a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the first quarter of 2023. “We continue to focus on growing high quality revenue streams, as we closely manage resources,” said Stan Jacot, president and CEO. “And the impact of this focus is clearly seen in our Q1 results, with notable improvements in gross profit dollars and operating expenses compared to last year...",
"Arcadia Biosciences, Inc. Consolidated Statements of Operations and Comprehensive Loss Three Months Ended March 31, 2023 2022 Revenues: Product $ 1,509 $ 3,170 Royalty — 50 Total revenues 1,509 3,220 Operating expenses : Cost of revenues 825 3,458 Research and development 359 395 Change in fair value of contingent consideration — Gain on sale of property and equipment Selling, general and administrative 4,392 4,349 Total operating expenses 5,557 7,843 Loss from operations # # # 1"
02/28/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ARCADIA BIOSCIENCES, INC. Arcadia Biosciences, Inc., a corporation organized under and existing under the laws of the State of Delaware , certifies that: FIRST: The name of the Corporation is Arcadia Biosciences, Inc. SECOND: The Board of Directors of the Corporation, acting in accordance with the provisions of Sections 141 and 242 of the Delaware General Corporation Law, duly approved and adopted resolutions to amend Article IV of the Amended and Restated Certificate of Incorporation of the Corporation, which is hereby amended to read in its entirety as follows: “ARTICLE IV A. Classes of Stock. The Corporation is authorized to issue two classes of stock to be designated, respectively, “Commo..."
02/22/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
12/08/2022 8-K Quarterly results
11/30/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
09/27/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/16/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
Docs: "Arcadia Biosciences Announces First Quarter 2022 Financial Results – Sales increased 48% from Q4 2021 – – First retail orders of Good WheatTM pasta shipped – -- HB4® soybeans approved in China, $2M milestone anticipated -- DAVIS, Calif. – Arcadia Biosciences, Inc.® , a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the first quarter of 2022. “Arcadia is starting to see the fruits of all its labor over the last year as we transitioned to a CPG-driven company and right-sized the organization,” said Stan Jacot, president and CEO of Arcadia Biosciences. “Sales have increased 48% compared to last quarter with a more agile organization and the lowest infrastructure costs since 2019. And our...",
"Arcadia Biosciences, Inc. Consolidated Balance Sheets Assets Current assets: Cash and cash equivalents $ 24,551 $ 28,685 Accounts receivable, net of allowance for doubtful accounts of $54 and $76 as of March 31, 2022 and December 31, 2021, respectively 2,768 1,370 Inventories, net — current 3,235 4,433 Assets held for sale 254 - Prepaid expenses and other current assets 691 900 Total current assets 31,499 35,388 Property and equipment, net 1,468 2,291 Right of use asset 2,546 3,081 Inventories, net — noncurrent 2,656 2,494 Intangible assets, net 471 484 Other noncurrent assets 159 180 Total assets $ 38,799 $ 43,918 Liabilities and stockholders’ equity Current liabilities: Accounts payable and accrued expenses $ 3,440 $ 3,638 Amounts due to related parties 69 64 Operating lease liability —..."
03/30/2022 8-K Quarterly results
Docs: "Arcadia Biosciences Announces Fourth-Quarter and Full-Year 2021 Financial Results and Business Highlights – Strong balance sheet entering 2022 – – Expanded consumer product offerings in on-trend categories – – Experienced CPG talent added throughout organization – DAVIS, Calif. – Arcadia Biosciences, Inc.® , a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the fourth quarter and full year of 2021. “Arcadia had an unprecedented year of transition and entered consumer-focused categories for the first time” said Stan Jacot, president and CEO of Arcadia Biosciences. “The acquisitions from 2021 have positioned us to broaden our reach within the health and wellness sector, and there are sig...",
"Arcadia Biosciences, Inc. Consolidated Balance Sheets As of December 31, 2021 2020 Assets Current assets: Cash and cash equivalents $ 28,685 $ 14,042 Short-term investments — 11,625 Accounts receivable, net of allowance for doubtful accounts of $76 and $0 as of December 31, 2021 and 2020, respectively 1,370 1,406 Inventories, net — current 4,433 3,812 Prepaid expenses and other current assets 900 811 Total current assets 35,388 31,696 Restricted cash — 2,001 Property and equipment, net 2,291 3,539 Right of use assets 3,081 5,826 Inventories, net — noncurrent 2,494 3,485 Goodwill — 408 Intangible assets, net 484 370 Other noncurrent assets 180 23 Total assets $ 43,918 $ 47,348 Liabilities and stockholders’ equity Current liabilities: Accounts payable and accrued expenses $ 3,638 $ 4,105 Am..."
02/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Release Deadline”), and if not, Executive will forfeit any right to severance payments or benefits under this Agreement. To become effective, the Release must be executed by Executive and any revocation periods must have expired without Executive having revoked the Release. In addition, in no event will severance payments or benefits be paid or provided until the Release actually becomes effective. If the termination of employment occurs at a time during the calendar year where the Release Deadline could occur in the calendar year following the calendar year in which Executive’s termination of employment occurs, then any severance payments or benefits under this Agreement that would be considered Deferred Payments ) will be paid on the first payroll date to occur during the calendar...",
"ARCADIA BIOSCIENCES, INC.",
"Investor Contact:"
12/20/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "[SIGNATURE PAGE TO SEPARATION AND RELEASE AGREEMENT] 9 | STOCK OPTIONS Grant Date Shares Subject to Stock Options Exercise Price Per Share 9/12/2016 6,250 $43.80 6/8/2017 11,250 $14.00 9/18/2018 47,200 $4.63 6/3/2019 26,000 $5.04 2/3/2020 76,000 $4.91 1/21/2021 250,000 $3.05 Total 416,700 10 |",
"Investor Contact:"
11/19/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/07/2021 8-K Quarterly results
08/16/2021 8-K Quarterly results
07/20/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/06/2021 8-K Quarterly results
07/02/2021 8-K Quarterly results
06/07/2021 8-K Quarterly results
05/21/2021 8-K Quarterly results
05/17/2021 8-K Quarterly results
03/30/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
01/29/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Form of Investor Warrant",
"Form of Placement Agent Warrant",
"Form of Securities Purchase Agreement, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto",
"Form of Registration Rights Agreement, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto"
12/22/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Form of Investor Warrant",
"Form of Placement Agent Warrant",
"Opinion of Weintraub Tobin Chediak Coleman Grodin Law Corporation",
"Form of Securities Purchase Agreement, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto",
"Master Transaction Agreement*+",
"Engagement Letter dated December 17, 2020, by and between the Arcadia Biosciences, Inc. and H.C. Wainwright & Co., LLC"
11/18/2020 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhi...
Docs: "Unaudited Pro Forma Condensed Consolidated Financial Information as of September 30, 2020, and December 31, 2019"
11/12/2020 8-K Quarterly results
Docs: "Arcadia Biosciences Announces Third-Quarter and Nine-Months September 30, 2020 Financial Results and Business Highlights"
08/13/2020 8-K Quarterly results
07/08/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy